| Subject: | FDA Issues Early Communication About Cardiovascular Events and Sibutramine |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 23 Nov 2009 - 10:00 am |
| The Food and Drug Administration (FDA) has notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo. Sibutramine, marketed as Meridia, was approved by FDA in 1997 for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with a... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
